3SBio Group

3Ssbio - A Pioneer and Undisputed Market Leader in the PRC Biotechnology Industry A pre-eminent player with 7 approved biological products in China’s fast growing biopharmaceutical industry Robust product pipeline – 28 candidates, among which 16 are being developed as National Class I drugs Augmented pipeline with monoclonal antibody (“mAb”) product candidates through acquisition of Guojian, including total 10 biological products (6 Class I drugs) State-of-the-art manufacturing facilities -11 antibody production lines with over 38,000 liter capacity -Small molecule production plant, mammalian cell based production plant, and bacterial cell based production plant Leading commercial platform with around 2,000 sales and marketing employee focusing on oncology, rheumatology, nephrology, metabolic and dermatology strong emphasis on academic marketing, covering over 6,000 hospitals and medical institutions, including over 2,000 Grade III hospitals（excluding hospitals covered by Byetta sales team）